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Objectives We studied whether the measurement of the soluble form of ST2 (sST2), an interleukin-1 receptor family mem-
ber, could identify heart failure (HF) patients at risk of sudden cardiac death (SCD).
Background The prediction of SCD remains an important challenge in patients with mild-to-moderate chronic HF. Concentra-
tions of sST2 have been found increased and related to worse long-term outcomes in patients with acute HF.
Whether sST2 has a prognostic role in SCD is unknown.
Methods A nested case-control study was performed on 36 cases of SCD and 63 control patients (matched for age, sex,
and left ventricular ejection fraction) obtained from the MUSIC (MUerte Súbita en Insuficiencia Cardı´aca) registry,
a 3-year multicenter registry of ambulatory HF patients (New York Heart Association functional class II to III, left
ventricular ejection fraction 45%). Demographic, clinical, echocardiographic, electrical, and biochemical data
were collected at enrollment.
Results Concentrations of sST2 were greater among decedents (0.23 ng/ml [interquartile range 0.16 to 0.43 ng/ml]
vs. 0.12 ng/ml [interquartile range 0.06 to 0.23 ng/ml], p  0.001) and were predictive of experiencing SCD
(0.1 ng/ml, odds ratio: 1.39, 95% confidence interval: 1.09 to 1.78, p  0.006). On the basis of a combined
biomarker status, only 4% of patients experienced SCD for neither sST2 nor N-terminal pro–B-type natriuretic
peptide (NT-proBNP) above receiver-operator characteristic-derived cut-off points (0.15 ng/ml and 2,000 ng/l,
respectively), 34% for either biomarker above, and 71% for both biomarkers above (p  0.001 for trend). This
combined variable added incremental prognostic value to the multivariable regression model (p  0.001).
Conclusions Elevated sST2 concentrations are predictive of SCD in patients with chronic HF and provide complementary infor-
mation to NT-proBNP levels. A combined biomarker approach may have an impact on clinical decision-making.
(J Am Coll Cardiol 2009;54:2174–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.041r
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ghe prediction and prevention of sudden cardiac death
SCD) remains a major challenge in the management of
atients with chronic heart failure (HF). Sudden cardiac
eath is the cause of 50% of all HF deaths, mainly affecting
atients with mild-to-moderate symptoms, and the number
f patients with HF at risk is increasing (1). The challenge
ies in identifying patients with HF who are at significant
rom *Cardiology Service, Virgen de la Arrixaca Hospital and Department of
edicine, University of Murcia, Murcia, Spain; †Biochemistry Service, Sant Pau
ospital and Department of Biochemistry and Molecular Biology, and the ‡Cardi-
logy Service, Sant Pau Hospital, Department of Medicine, Universitat Autònoma de
arcelona, Barcelona, Spain; §Biochemistry Service, Virgen de la Arrixaca Hospital,
urcia, Spain; Cardiology Service, Hospital Universitario Puerta del Mar, Ca´diz,pain; and the ¶Institut Català de Ciències Cardiovasculars, Barcelona, Spain. This
tudy was supported by “Red Tema´tica de Investigacio´n Cooperativa MUSIC” and
tisk of SCD. Severe left ventricular (LV) systolic dysfunc-
ion has long been recognized as a risk factor for SCD, yet
eft ventricular ejection fraction (LVEF) lacks enough sen-
itivity and specificity by itself (2,3). Among electrical
actors, there is evidence that prolonged QRS duration and
he presence of nonsustained ventricular tachycardia may
dentify a subset of patients at greater risk of SCD (4,5).
he national network of investigation on heart failure “REDINSCOR”: Grants
03/078 and RD06/0003, Instituto de Salud Carlos III, Ministry of Health, Madrid,
pain. Dr. Pascual-Figal has received speaking and research grants from Roche
iagnostics. Dr. Ordoñez-Llanos has received speaking, consulting, and research
rants from Roche Diagnostics. Dr. Bayes-Genis has received speaking and research
rants from Roche Diagnostics. Critical Diagnostics freely provided the reagents used
o measure sST2. The first 2 authors contributed equally to this work.
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December 1, 2009:2174–9 sST2 and Sudden Cardiac Death in HFatriuretic peptides also have been associated with a greater
isk of SCD (6–9). The mechanism of SCD remains
ncertain, and additional diagnostic tests to replace or
omplement currently existing tools are required for a better
rediction of SCD in patients with HF (10,11).
ST2, an interleukin (IL)-1 receptor family member, has
een identified as a novel biomarker for cardiac strain
12,13). Under the induction of separate promoters, the ST2
ene expresses 2 unique proteins: sST2, the circulating form
f ST2, and ST2L, which is the transmembrane receptor
orm and signals through a complex involving IL-33 (14–
6). This IL-33/ST2L signaling plays a previously unrec-
gnized cardioprotective role in mechanical overload and
xerts antifibrotic actions (17,18). Sanada et al. (17) dem-
nstrated that the sST2 protein acts as a decoy receptor,
eversing the protective effects of IL-33/ST2L in a dose-
ependent manner, probably by binding IL-33 and prevent-
ng signaling through ST2L. Thus, it is postulated that
ST2 could be a potential pathophysiological mediator of
yocardial fibrosis.
Concentrations of sST2 have been found to be predictive
f the rate of mortality in acute coronary syndromes (19,20)
nd also in the long-term follow-up of patients after an
cute HF episode (21–23). Whether sST2 could have a role
n the identification of patients at risk of SCD is not known.
n the basis of its fibrosis-modulating effect (17,18) and the
nteraction between cardiac fibrosis and electrical heteroge-
eity in SCD (11); we hypothesized that sST2 could
dentify patients at risk of SCD and add useful prognostic
nformation for stratifying care. The aim of this study was to
nvestigate such prognostic value in a nested case-control
tudy of patients with mild-to-moderate HF and LV
ystolic dysfunction.
ethods
tudy population and protocol. The study was a post-hoc,
ested case-control study of participants included in the
USIC (MUerte Súbita en Insuficiencia Cardı´aca) study
24,25), a prospective multicenter longitudinal study de-
igned to assess risk predictors of cardiac mortality and SCD
n patients with HF in New York Heart Association
unctional class II to III. Participants were those patients
onsecutively enrolled in 3 specialist HF clinics, between
pril 2003 and December 2004, with both LVEF 45%
nd absence of an implanted cardiac defibrillator (n  356).
ll patients received standard management as recom-
ended by contemporary guidelines, including pharmaco-
ogic therapy at the maximal tolerated doses (angiotensin-
onverting enzyme inhibitor or angiotensin receptor blocker
3%, beta-blockers 73%, loop diuretics 86%, spironolactone
6%, digoxin 40%).
All patients were followed for 3 years, and case partici-
ants (n 36) consisted of all individuals who died of SCD.
fter identifying cases of SCD, controls were those patients
ho remained alive during follow-up (3 years; n  247). Hatients were sorted according to
he time of inclusion, and we
ttempted to match 2 control
atients to each case by using the
earest control subjects that ful-
lled the following criteria: same
ex, age within 5 years, and
VEF  5%. A total of 63
ontrol subjects were matched to
ases. The STROBE (Strength-
ning the Reporting of Observa-
ional Studies in Epidemiology)
ecommendations (26) were used
n the development of the study.
Detailed information about
ymptoms, clinical history, 12-lead
lectrocardiogram, and medication
sage was collected at baseline. An
chocardiogram was performed at
aseline in all patients, and stan-
ardized measures were obtained
ccording to the American Society
f Echocardiography recommen-
ations (27). The 24-h ambulatory 3-channel electrocardio-
raphic recordings were obtained at baseline and analyzed by
he use of ELA Synescope Holter software (ELA Medical,
orin Group, Paris, France) to evaluate the presence of
entricular arrhythmias. The study protocol was approved by
he respective institutional investigation committees, and all
atients signed informed consent. Follow-up visits were con-
ucted on an outpatient basis every 6 months or according to
atients’ clinical status for 3 years.
efinition of SCD. Cases of death were verified by hos-
ital and autopsy records and by either relatives or the
rimary physicians who had witnessed the death. Death was
efined as “sudden cardiac death” (28) by an “ad-hoc
ommittee” (R.V., J.C., A.B.d.L., and A.B.-G.) if it was:
) a witnessed death occurring within 60 min from the onset
f new symptoms, unless a cause other than cardiac was
bvious; 2) an unwitnessed death (24 h) in the absence of
re-existing progressive circulatory failure or other causes of
eath; or 3) a death during attempted resuscitation.
iochemical analysis. Blood samples were obtained by ve-
ipuncture at patient enrollment and aliquots of serum stored
t –80°C until analyzed. Concentrations of sST2 were deter-
ined by the use of an enzyme-linked immunosorbent assay
rom Medical & Biological Laboratories Co. (no. 7638,
oburn, Massachusetts) (12). This nonautomated assay,
hich uses monoclonal antibodies to human sST2 for both
apture and detection of sST2, requires several manual steps,
nd its total imprecision at the concentration found as cut-off
oint (0.150 ng/ml) was of 18.5% (ranging from 5.7% at 4.0
g/ml to 20% at 0.0625 ng/ml). The total imprecision we
ound was close to the recommended as desirable (15%) in
nternational guidelines (29) for the cut-off values of similar
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CI  confidence interval
HF  heart failure
IL  interleukin
IQR  interquartile range
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
OR  odds ratio
ROC  receiver-operator
characteristic
SCD  sudden cardiac
death
sST2  soluble ST2F biomarkers, as B-type natriuretic peptides (BNPs), mea-
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sST2 and Sudden Cardiac Death in HF December 1, 2009:2174–9urable with fully automated methods. N-terminal pro–B-type
atriuretic peptide (NT-proBNP) levels were measured at the
ime of patient inclusion by electrochemiluminescence immu-
oassay by the use of an Elecsys 2010 analyzer (Roche
iagnostics GmbH, Mannheim, Germany) with a total im-
recision 3% (30). Both sST2 and NT-proBNP were eval-
ated in a central laboratory (J.O.-L).
tatistical analysis. Continuous variables were tested for
ormal distribution by use of the Kolmogorov-Smirnov test.
ariables not normally distributed are expressed as median
interquartile range [IQR]). Normally distributed continu-
us variables are expressed as mean  SD. Frequencies of
ategorical variables were expressed as numbers (percentage)
nd compared by the Fisher exact test. The comparison of
ontinuous variables between the 2 groups was carried out
y use of the Mann-Whitney U nonparametric test.
eceiver-operating characteristic (ROC) curve analysis was
onstructed to determine the optimal cut-off points for
T-proBNP and sST2 for predicting SCD. A new ordinal
alue was built on the basis of a combined biomarker status,
aking into account the presence of neither, either, or both
iomarkers above the ROC-derived cut-off points.
Univariable logistic regression analysis was used for studying
he association between SCD and biomarkers and was evalu-
ted as continuous variables and as the new combined ordinal
ariable. The clinical, electrical, echocardiographic, and bio-
hemical characteristics are described in Table 1 were also
valuated in the univariable logistic regression analysis. Vari-
bles that showed a significant result (p 0.05) were included
n the multivariable logistic regression model (forward step-
ise) to determine those independently related to SCD. The
ncremental information added by sST2 was studied by taking
he optimal regression multivariable model and then adding
ST2 to this model. The combined variable sST2/NT-
roBNP also was the last variable put into the multivariable
odel to assess its incremental value added to the other
ariables. All tests were 2-sided, and a p value 0.05 was
onsidered statistically significant. All data analyses were per-
ormed by the use of SPSS version 15.0 software (SPSS Inc.,
hicago, Illinois).
esults
he characteristics of SCD patients (cases) and HF survivors
control subjects) are shown in Table 1. After enrollment, the
ajority (53%) of SCD cases occurred during the first year; the
ollow-up in the SCD group had a median of 10.8 months
IQR 6.4 to 20.1 months). Decedents and controls were
atched by age, sex, and LVEF; yet among SCD patients,
revious myocardial infarction was slightly more prevalent, and
ifferences between groups also were found for New York
eart Association functional class, left atrial diameter, and
lomerular filtration rate. No group differences were observed
n the other clinical, echocardiographic, electrical, or biochem-
cal parameters. As shown in Figure 1, concentrations at
nrollment of sST2 (0.23 ng/ml [IQR 0.16 to 0.43 ng/ml] vs. 0.12 ng/ml [IQR 0.06 to 0.23 ng/ml], p  0.001) and
T-proBNP (2,873 ng/l [IQR 1,541 to 6,979 ng/ml] vs. 966
g/l [IQR 440 to 2,405 ng/ml], p  0.001) were significantly
reater in patients who experienced SCD during the 3-year
ollow-up. In the logistic regression analysis, sST2 levels (0.1
g/ml, odds ratio [OR]: 1.39, 95% confidence interval [CI]:
.09 to 1.78, p  0.006) and NT-proBNP levels (OR: 1.02,
5% CI: 1.00 to 1.03, p  0.01) were predictive of SCD.
Figure 2 illustrates the ROC curves for both sST2 and
T-proBNP, which identified the following optimal cut-off
oint values: 0.15 ng/ml for sST2 and 2,000 ng/l for
T-proBNP. When these values were used to predict
utcome, sST2 had 83% sensitivity (95% CI: 67% to 94%),
1% specificity (95% CI: 38% to 64%), a positive predictive
alue of 49%, and a negative predictive value of 84%; and
T-proBNP had 72% sensitivity (95% CI: 53% to 86%),
3% specificity (95% CI: 60% to 83%), a positive predictive
alue of 58%, and a negative predictive value of 83%.
After adjustment in the multivariable model, introducing
ariables with a univariate difference between groups and
xcluding sST2, the independent predictors were left atrial
iameter (OR: 1.12, 95% CI: 1.032 to 1.231, p  0.006),
stimated glomerular filtration rate (OR: 0.956, 95% CI:
haracteristics of SCD (Cases)nd Survivors (Control Subjects)Table 1 Characteristics of SCD (Cases)and Survivors (Control Subjects)
SCD
(n  36)
Survivors
(n  63)
p
Value
Demographic and clinical
Age, yrs 66 11 65 9 0.30
Sex, male 83% 83% 0.92
Body mass index, kg/m2 27.4 4.5 27.7 4.3 0.69
Hypertension 50% 52% 0,82
Diabetes mellitus 50% 41% 0.40
Previous myocardial infarction 64% 41% 0.03
NYHA functional class II versus III 50%, 50% 78%, 22% 0.005
Heart rate, beats/min 72 18 69 15 0.87
Systolic blood pressure, mm Hg 113 17 119 17 0.11
Electrical
Sinus rhythm 56% 67% 0.47
QRS length, ms 134 33 127 33 0.31
VPB, per h 28 (6199) 30 (13103) 0.87
Nonsustained VT 50% 54% 0.70
Echocardiographic
IV septum thickness, mm 11.1 2.3 10.8 2.2 0.49
Left atrial diameter, mm 51 9 44 7 0.001
LVEDD, mm 65 8 64 9 0.45
LVEF, % 29 8 31 8 0.14
Biochemical
eGFR, ml/min 53 15 64 14 0.001
Hemoglobin, g/dl 13.3 15.4 13.7 15.7 0.25
Sodium, mEq/l 139 3 139 3 0.72
Potassium, mEq/l 4.4 0.6 4.6 0.5 0.06
ata are presented as %, mean  SD, and median (interquartile range).
eGFR  estimated glomerular filtration rate by Modification of Diet in Renal Disease equation;
V  interventricular; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular
jection fraction; NYHA  New York Heart Association; SCD  sudden cardiac death; VPB 
entricular premature beats; VT  ventricular tachycardia..918 to 0.995, p  0.01), and NT-proBNP 2,000 ng/l
(
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December 1, 2009:2174–9 sST2 and Sudden Cardiac Death in HFOR: 5.46, 95% CI: 1.85 to 16.1, p  0.002; chi-square 
2.2). When added to this model, sST2 0.15 ng/ml was
n independent predictor of SCD (OR: 4.56, 95% CI: 1.31
o 15.9, p  0.017) and added incremental value to the
odel (chi-square: 48.6, p  0.012).
In a combined biomarker approach, the presence of none,
ither (p  0.015), or both elevated biomarkers (p  0.001)
ere predictive of SCD (p  0.001 for trend). As shown in
able 2, this combined variable added incremental prognostic
alue to the multivariable regression model (p  0.001). The
resence of none, 1, or 2 elevated biomarkers was associated
ith increasing rates of SCD (Fig. 3); only 4% of patients
xperienced SCD for neither sST2 nor NT-proBNP above the
OC-derived cut-off points; 34% for either biomarker above
nd 71% for both biomarkers above.
iscussion
his study shows that increased serum levels of sST2, a
ovel biomarker of cardiac strain, were predictive of SCD in
mbulatory patients with mild-to-moderate chronic HF and
Figure 1 sST2 and NT-proBNP in
Patients With SCD and Survivors
Box plots showing the baseline concentrations of soluble ST2 (sST2) (A) and
N-terminal pro–B-type natriuretic peptide (NT-proBNP) (B) in patients experienc-
ing sudden cardiac death (SCD) and the control survivor group.eft ventricular systolic dysfunction. The prognostic value of
A
NST2 was independent of other clinical variables and, impor-
antly, provided complementary information to NT-proBNP.
This study is the first to demonstrate a significant
ssociation between this novel biomarker and SCD. The
uthors of previous reports (22,23) already recognized sST2
s a powerful prognosticator for all-cause mortality during
he long-term follow-up (1 year) in patients with acute HF.
n our population, sST2 added independent prognostic
nformation to predict SCD over the other studied variables,
ncluding NT-proBNP. Therefore, this study provides new
ata about the prognostic value of sST2 in the ambulatory
Figure 2
Receiver-Operator Characteristic Curve Analysis
of sST2 and NT-proBNP Concentrations for
Predicting SCD
AUC  area under the curve; other abbreviations as in Figure 1.
ultiple Regression Analysis:djusted Mod l for Prediction of SCDTable 2 Mult ple R gression Analysis:Adjusted Models for Prediction of SCD
Chi-Square OR (95% CI) p Value
sST2/NT-proBNP not included 27.7
Previous AMI — 0.15
NYHA functional class III 3.050 (1.138.20) 0.027
LA, mm 1.178 (1.061.31) 0.003
eGFR, 10 ml/min 0.955 (0.920.99) 0.013
sST2/NT-proBNP included 45.0
Previous AMI — 0.25
NYHA functional class III — 0.23
LA, mm 1.12 (1.031.23) 0.007
eGFR, 10 ml/min 1.05 (1.011.10) 0.01
sST2/NT-proBNP 0.004
Either elevated 11.9 (1.4102) 0.024
Both elevated 37.3 (4.0350) 0.002MI  acute myocardial infarction; CI  confidence interval; LA  left atrium; NT-proBNP 
-terminal pro–B-type natriuretic peptide; OR  odds ratio; other abbreviations as in Table 1.
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sST2 and Sudden Cardiac Death in HF December 1, 2009:2174–9etting of chronic HF and the complementary roles of sST2
nd NT-proBNP. Such a multimarker predictive approach,
ST2 plus NT-proBNP, also has been reported in patients
ith acute coronary syndromes and acute HF (20,22,23). In
ur HF population, elevation of both biomarkers above the
ut-off values was associated with a very high rate (71%) of
CD, and interestingly, a very low rate (4%) of SCD existed
hen both markers were below the cut-off thresholds. At
resent, no single test reliably predicts SCD in patients with
F (10), but the combination of sST2 and NT-proBNP
arkedly improves risk stratification to identify high- and
ow-risk patients; this fact, may have an important impact
n clinical decision-making, particularly for delineating
ptimal preventive strategies.
It is noticeable that the sST2 cut-off value for SCD in
F patients found in this study (0.150 ng/ml) is very close
o the 95 percentile of a blood donor population found by
ehman et al. (22) (0.168 ng/ml) and to the cut-off value
ound in the PRIDE (Pro-Brain Natriuretic Peptide Inves-
igation of Dyspnea in the Emergency Department) study
o predict 1-year mortality in acutely dyspneic and acute HF
atients (0.200 ng/ml) (31). Therefore, our results support
he evidence of a “solid” cut-off value between 0.150 and
.200 ng/ml for predicting and ruling-out major cardiac
vents in HF patients. It is likely that sST2 may fluctuate
ver time, as occurs with BNP, and it has been reported that
hanges in sST2 concentrations have also a prognostic value
21,32). In this study, we did not collect serial sST2
easures to explore the effect of changes over time, yet the
resented data support the predictive value of a single
Figure 3
Events According to the Presence of None,
Either, or Both sST2 >0.15 ng/ml and
NT-proBNP >2,000 ng/l
Red bars  sudden cardiac death;
open bars  survivors. Abbreviations as in Figure 1.nclusion measurement. FThe relationship between ST2 and SCD is at present
ncompletely characterized, but some hypothesis could arise
ased on the physiology of IL-33/ST2 pathway. IL-33/ST2
as emerged as an intercellular signaling system that par-
icipates in inflammatory responses, autoimmunity, organ
brosis, and cardiac injury (18). IL-33/ST2 signaling pro-
ects the myocardium under mechanical strain and acts as a
iomechanically activated fibroblast-cardiomyocyte para-
rine system that prevents cardiac hypertrophy and fibrosis
17,18). Sanada et al. (17) suggest that sST2 protein
brogates this adaptative response in a dose-dependent
anner by binding IL-33 and preventing signaling through
T2L. Moreover, IL-33/ST2 system might participate in
nflammatory and remodeling processes of the myocardium
15,33). Concentration of sST2 correlate positively with
arameters of HF severity, as norepinephrine levels, natri-
retic peptides levels, diastolic filling pressures, and
-reactive protein levels (21–23,34). It is thus possible that
ST2 is not only a biomarker of outcome but also a true
athophysiological mediator of disease progression and
redisposition to SCD.
sST2 modulates extracellular matrix remodeling and reg-
lates inflammatory and electrical signals between cardiac
ells types that may facilitate lethal cardiac arrhythmias
18,35) or other cardiac events ultimately leading to SCD.
oreover, its relationship with fibrosis and inflammation
ould explain its complementary role with NT-proBNP; in
act, procollagen and high-sensitivity C-reactive protein
lso have been shown to be complementary of BNP in the
rediction of ventricular tachycardia, among patients with
mplanted cardioverter-defibrillator (9).
Sudden cardiac death is a hard end point in patients with
F, yet this mode of death is difficult to obtain, and it has been
ainly evaluated by clinical trials of primary prevention. The
egistry from which current data were obtained was specifically
esigned to study SCD, and therefore patients were closely
ollowed and the mode of death rigorously verified by an
ndependent “ad-hoc committee,” as prespecified. However,
ithout cardiac monitoring at the time of death, the assump-
ion of an underlying arrhythmic cause is only presumptive.
fter 3 years of follow-up, 36 sudden deaths were identified.
his is a large group of SCD patients, comparable or greater
han those of several published clinical trials on sudden death
4–8,28,36). The greatest-risk patients, those who already
ad a defibrillator implanted, were excluded. Nevertheless,
lthough the highest- and lowest-risk patients obtain less
enefit from risk stratification, the patients at an interme-
iate risk, like those included in this study, are most
enefited by SCD prediction.
onclusions
his is the first study to demonstrate that elevated sST2
oncentrations are predictive of SCD and provide comple-
entary information to clinical variables and NT-proBNP.
uture trials are needed to elucidate whether this novel
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December 1, 2009:2174–9 sST2 and Sudden Cardiac Death in HFiomarker, alone or in combination with NT-proBNP, is
seful in clinical routine for preventing SCD.
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